IDEAYA Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2017
Net Income	-128.89	-112.96	-58.66	-49.76	-34.5	-41.98	Upgrade
Depreciation & Amortization	4.13	4.01	3.52	3.03	1.38	1.25	Upgrade
Share-Based Compensation	21.14	18.49	11.63	8.24	3.61	2.17	Upgrade
Other Operating Activities	-27.57	-24.76	-43.66	-17.29	84.97	-0.75	Upgrade
Operating Cash Flow	-131.2	-115.22	-87.18	-55.78	55.46	-39.31	Upgrade
Capital Expenditures	-3.65	-2.37	-3.44	-2.64	-0.49	-1.35	Upgrade
Change in Investments	-532.3	-156.09	-29.96	-67.02	-145.75	3.62	Upgrade
Investing Cash Flow	-535.95	-158.46	-33.4	-69.67	-146.24	2.27	Upgrade
Share Issuance / Repurchase	666.72	320.54	97.17	145.45	128.75	50.61	Upgrade
Other Financing Activities	42.18	42.18	-	-	-	-	Upgrade
Financing Cash Flow	708.9	362.72	97.17	145.45	128.75	50.61	Upgrade
Net Cash Flow	41.76	89.04	-23.41	20.01	37.97	13.56	Upgrade
Free Cash Flow	-134.85	-117.59	-90.62	-58.42	54.97	-40.67	Upgrade
Free Cash Flow Margin	-869.74%	-502.85%	-177.92%	-209.09%	281.35%	-	Upgrade
Free Cash Flow Per Share	-1.79	-2.04	-2.19	-1.66	2.22	-3.25	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).